The new global CEO for SHL Medical Holding will be Ulrich Faessler. Ulrich has been with SHL for over seven years and has been the Asian Managing Director for SHL Medical for the past five years.
Menu
The rapid growth of the biologics and biosimilars market has created a significant demand for self-injection devices for the treatment of chronic indications.
At the center of this exhibition are designs for high volume and high viscosity formulations.
Combining internal knowledge and experience with active partnerships, SHL has launched a number of initiatives in the digital space for drug delivery systems.
SHL Group has announced that it will be holding a webinar discussing…
The rapid growth of biologics and biosimilars has significantly increased the demand for self-injection devices for the treatment of chronic indications.
An article examining SHL’s patient-centric approach to industrial designs was published in the May 2017 issue of OnDrugDelivery Magazine.
The growing demand for treatments using biological drugs has created a challenge for injectable devices to deliver next-generation, high viscosity formulations all the while putting patient comfort and usability first.
SHL will also show the highly-anticipated ENYA Platform, a smart add-on injection tracking offering developed in partnership with Innovation Zed Ltd.
